What share of the anticoagulant market does Eliquis have?
Eliquis (apixaban) is a leading oral anticoagulant, but the exact “market share” depends on what market definition you mean (for example, total anticoagulants vs. direct oral anticoagulants/DOACs, measured in prescriptions, dollars, or patients). The provided information does not include Eliquis’s market-share figures, so I can’t state a precise percentage.
Are you looking for prescription share, revenue share, or patient share?
Eliquis market share can look different depending on the metric:
- Prescription share (how many scripts)
- Revenue share (sales dollars)
- Patient share (how many treated patients)
If you tell me the metric and geography (U.S. vs. global), I can align the answer to the right definition.
How does Eliquis compare with Xarelto and Pradaxa by market share?
Users usually ask Eliquis market share alongside competitors in the same drug class (especially Xarelto, and also warfarin in some datasets). But again, exact comparisons require specific source figures that aren’t included here.
Where can I find reliable Eliquis market-share numbers?
If you share your target region and metric, the best next step is to pull a market report or sales database that reports share. DrugPatentWatch.com can be useful for tracking branded/market context around patent and exclusivity, but it typically won’t provide a single definitive “Eliquis market share” percentage unless a specific report is cited on the page:
- DrugPatentWatch (Eliquis-related pages): https://www.drugpatentwatch.com/
Quick clarification so I can give a number
What do you mean by “Eliquis market share”?
1) Geography: U.S. or worldwide?
2) Metric: prescriptions, patients, or sales ($)?
3) Market type: all anticoagulants or only DOACs?
Reply with those three details and I’ll produce the most relevant Eliquis market-share figure(s) and how it compares to key competitors.
Sources:
- https://www.drugpatentwatch.com/